SCHEMBL134607

SCHEMBL134607

COC(=O)Cc1ccc(OC)c(-c2ccc(C)cc2C=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.47
RIN1 Q13671 1/20 0.47
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
EPHX2 P34913 1/20 0.43
GAA P10253 3/20 0.43
SRC P12931 1/20 0.41
LMNA P02545 2/20 0.40
RECQL P46063 1/20 0.40
ALDH1A1 P00352 3/20 0.40
GFER P55789 1/20 0.40
ERN1 O75460 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTSD P07339 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136891 0.91 ABL1 (0.46) ABL1RIN1L3MBTL1EPHX2GAA
SCHEMBL137398 0.89 GAA (0.51) ABL1RIN1GAASRCALDH1A1
SCHEMBL137399 0.85 SRC (0.41) ABL1RIN1L3MBTL1GAASRC
SCHEMBL3409572 0.85 JAK2 (0.50) JAK2JAK3GAAALDH1A1GFER
SCHEMBL1641289 0.84 PDK2 (0.42) JAK2JAK3GAAALDH1A1GFER
SCHEMBL137376 0.84 PTGDR2 (0.53) PTGDR2
SCHEMBL17124777 0.83 JAK2 (0.55) ABL1RIN1JAK2JAK3EPHX2
SCHEMBL134674 0.82 ABL1 (0.49) ABL1RIN1JAK2JAK3L3MBTL1
SCHEMBL1641291 0.82 JAK2 (0.40) ABL1RIN1JAK2JAK3GAA
SCHEMBL137406 0.81 ABL1 (0.48) ABL1RIN1JAK2JAK3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524748-B2 Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-09-03 US disclosed
US-8497381-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-07-30 US disclosed
US-20130158036-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2013-06-20 US disclosed
US-8362044-B2 N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-01-29 US disclosed
US-20120058123-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC. (US) 2012-03-08 US disclosed
US-20110245303-A1 HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-10-06 US disclosed
US-20110039852-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
US-20110021573-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158036-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 ABL1 3888/4885RIN1 4058/4885JAK2 2034/4885
US-20110039852-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 ABL1 3888/4885RIN1 4058/4885JAK2 2034/4885
US-20120058123-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 ABL1 3888/4885RIN1 4058/4885JAK2 2034/4885
US-20110021573-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 ABL1 4601/4885RIN1 4059/4885JAK2 1053/4885
US-20110245303-A1 HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 ABL1 4317/4885RIN1 4416/4885JAK2 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.